Home / VEGF-B / Human VEGF-B167/186 Antibody

Human VEGF-B167/186 Antibody

Catalog #: AF751
9 Citations Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
AF751
AF751-SP
Detection of Mouse VEGF-B by Western Blot
2 Images
Product Details
Citations (9)
FAQs
Supplemental Products
Reviews
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human VEGF-B167/186 Antibody Summary

Species Reactivity
Human
Specificity
Detects human VEGF-B167 and human VEGF-B186 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant mouse (rm) VEGF-B186, rmVEGF-B167, rmVEGF-B206, recombinant human (rh) VEGF-A, rhVEGF-C, and rhVEGF-D is observed.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
E. coli-derived recombinant human VEGF-B186
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Applications

Recommended Concentration
Sample
Western Blot
0.1 µg/mL
Recombinant Human VEGF-B167 (Catalog # 751-VE) and Recombinant Human VEGF-B186

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot Detection of Mouse VEGF-B by Western Blot View Larger

Detection of Mouse VEGF-B by Western Blot Expression patterns of CCR2, VEGFA, and VEGFB protein in wounded corneas of WT and MMP12 KO mice. (A) Protein expression levels of CCR2 and actin in unwounded and wounded corneas of WT (N = 8 per lane) and Mmp12−/− (N = 8 per lane) mice 1 and 6 days post-chemical injury, as determined by Western blot analysis. Full-length blots are presented in Supplementary Fig. 1A. (B,C) The effect of CCL2 neutralization on VEGFA and VEGFB protein expression in WT and Mmp12−/− mice at 7 days post-chemical injury. Treatment of WT and Mmp12−/− mice with PBS or anti-CCL2 antibody had no significant effect on VEGFA expression. Treatment of Mmp12−/− mice with anti-CCL2 significantly decreased VEGFB protein expression compared with PBS-treated Mmp12−/− mice (0.42 versus 0.065 respectively). VEGFB expression was decreased more in WT mice compared with Mmp12−/− mice following treatment with anti-CCL2 (0.24 versus 0.065 respectively). *P < 0.05. Full-length blots are presented in Supplementary Fig. 1B,C. While we had to use several gels to fit all samples, they all derive from the same experiment and gels/blots were processed in parallel. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/31399604), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Mouse VEGF-B by Western Blot View Larger

Detection of Mouse VEGF-B by Western Blot Expression patterns of CCR2, VEGFA, and VEGFB protein in wounded corneas of WT and MMP12 KO mice. (A) Protein expression levels of CCR2 and actin in unwounded and wounded corneas of WT (N = 8 per lane) and Mmp12−/− (N = 8 per lane) mice 1 and 6 days post-chemical injury, as determined by Western blot analysis. Full-length blots are presented in Supplementary Fig. 1A. (B,C) The effect of CCL2 neutralization on VEGFA and VEGFB protein expression in WT and Mmp12−/− mice at 7 days post-chemical injury. Treatment of WT and Mmp12−/− mice with PBS or anti-CCL2 antibody had no significant effect on VEGFA expression. Treatment of Mmp12−/− mice with anti-CCL2 significantly decreased VEGFB protein expression compared with PBS-treated Mmp12−/− mice (0.42 versus 0.065 respectively). VEGFB expression was decreased more in WT mice compared with Mmp12−/− mice following treatment with anti-CCL2 (0.24 versus 0.065 respectively). *P < 0.05. Full-length blots are presented in Supplementary Fig. 1B,C. While we had to use several gels to fit all samples, they all derive from the same experiment and gels/blots were processed in parallel. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/31399604), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGF-B

Vascular endothelial growth factor B (VEGF-B), also known as vascular endothelial growth factor-related factor (VRF), is a member of the VEGF family of growth factors that share structural and functional similarity (1, 2). Five mammalian members, including VEGF-A, -B, -C, -D and PlGF, have been identified. VEGF family members are disulfide-linked dimeric proteins that are important regulators of physiological and pathological vasculogenesis, angiogenesis and lymphangiogenesis. VEGF-B is expressed in most tissues, especially in heart, skeletal muscle and pancreas. In many tissues, VEGF-B is co-expressed and can heterodimerize with VEGF (3). By alternative splicing, two isoforms of mature VEGF-B containing 167 or 186 amino acid (aa) residues exist (3, 4). The two VEGF-B isoforms have identical amino-terminal cysteine-knot VEGF homology domains but the carboxyl end of VEGF-B167 differs from that of VEGF-B186 by the presence of a highly basic cysteine-rich heparin binding domain. Whereas VEGF-B186 is a secreted diffusible protein, VEGF-B167 is sequestered into the cell matrix after secretion. Both VEGF-B isoforms bind VEGF receptor 1 (VEGF R1), but not VEGF R2 or VEGF R3 (5). On endothelial cells, ligation of VEGF R1 by VEGF-B has been shown to regulate the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1. VEGF-B167 and a proteolytically processed form of VEGF-B186 (VEGF-B127) also bind neuropilin-1 (NP-1), a type I transmembrane receptor for semaphorins/collapsins, ligands involved in neuron guidance (6). Besides VEGF-B, NP-1 has been shown to bind PLGF-2, VEGF165 and VEGF R1 (6, 7). The many interactions of NP-1 with VEGF ligands and receptor suggests that NP-1 may function as a regulator of angiogenesis (7).

References
  1. Li, X. and U. Eriksson (2001) Int. J. Biochem Cell Biol. 33:421.
  2. Olofsson, B. et al. (1999) Curr. Opin. Biotechnol. 10:528.
  3. Olofsson, B. et al. (1996) Proc. Nat. Acad. Sci. USA 93:2576.
  4. Grimmond, S. et al. (1996) Benome Res. 6:124.
  5. Olofsson, B. et al. (1998) Proc. Nat. Acad. Sci. USA 95:11709.
  6. Makinen, T. et al. (1999) J. Biol. Chem. 274:21217.
  7. Fuh, G. et al. (2000) J. Biol. Chem. 275:26690.
Long Name
Vascular Endothelial Growth Factor B
Entrez Gene IDs
7423 (Human); 22339 (Mouse)
Alternate Names
vascular endothelial growth factor B; VEGFB; VEGF-B; VEGF-related factor; VRFVEGFL

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human VEGF-B167/186 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

9 Citations: Showing 1 - 9
Filter your results:

Filter by:

  1. MMP12 Inhibits Corneal Neovascularization and Inflammation through Regulation of CCL2.
    Authors: Wolf M, Clay S. M, et al.
    Sci Rep
  2. Vascular Endothelial Growth Factor-B Induces a Distinct Electrophysiological Phenotype in Mouse Heart
    Authors: Nikolay Naumenko, Jenni Huusko, Tomi Tuomainen, Jussi T. Koivumäki, Mari Merentie, Erika Gurzeler et al.
    Frontiers in Physiology
  3. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.
    Authors: Fan F, Samuel S, Gaur P
    Br. J. Cancer, 2011-03-15;104(8):1270-7.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  4. Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells.
    Authors: Fan F, Gray MJ, Dallas NA, Yang AD, Van Buren G, Camp ER, Ellis LM
    Mol. Cancer Ther., 2008-09-01;7(9):3064-70.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  5. Upregulation of VEGF-A without angiogenesis in a mouse model of dilated cardiomyopathy caused by mitochondrial dysfunction.
    Authors: Tham E, Wang J, Piehl F, Weber G
    J. Histochem. Cytochem., 2002-07-01;50(7):935-44.
    Species: Mouse
    Sample Types: Tissue Homogenates
    Applications: Western Blot
  6. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome.
    Authors: Zhou Y, 2019, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ
    2002-04-01;160(4):1405-23.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  7. Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects.
    Authors: Okruzhnov Y, Nicholas J
    J. Virol., 2001-11-01;75(22):10933-40.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  8. Adenoviral VEGF-B186R127S gene transfer induces angiogenesis and improves perfusion in ischemic heart
    Authors: Henna Korpela, Olli-Pekka Hätinen, Tiina Nieminen, Rahul Mallick, Pyry Toivanen, Jonna Airaksinen et al.
    iScience
  9. Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy
    Authors: Reetta A. E. Eriksson, Tiina Nieminen, Lionel Galibert, Sanna K. Peltola, Petra Tikkanen, Piia Käyhty et al.
    Frontiers in Medicine

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human VEGF-B167/186 Antibody

There are currently no reviews for this product. Be the first to review Human VEGF-B167/186 Antibody and earn rewards!

Have you used Human VEGF-B167/186 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review